• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by TELA Bio Inc.

    5/8/25 7:57:51 AM ET
    $TELA
    Medical/Dental Instruments
    Health Care
    Get the next $TELA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 4)


    TELA Bio, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    872381108

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    872381108


    1Names of Reporting Persons

    Orin Hirschman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,416,323.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,416,323.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,416,323.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.6 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    872381108


    1Names of Reporting Persons

    AIGH Capital Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,416,323.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,416,323.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,416,323.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.6 %
    12Type of Reporting Person (See Instructions)

    IA, OO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    TELA Bio, Inc.
    (b)Address of issuer's principal executive offices:

    1 Great Valley Parkway Suite 24 Malvern PA 19355
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is being jointly filed by each of the following persons pursuant to Rule 13d-1 promulgated by the Securities and Exchange Commission pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the "Act"): (i) AIGH Capital Management, LLC, a Maryland limited liability company ("AIGH CM"), as an Advisor or Sub-Advisor with respect to shares of Common Stock (as defined in Item 2(d) below) held by AIGH Investment Partners, L.P., and WVP Emerging Manger Onshore Fund, LLC - AIGH Series. (ii) AIGH Investment Partners, L.L.C., a Delaware limited liability company ("AIGH LLC";), with respect to shares of Common Stock (as defined in Item 2(d) below) directly held by it; (iii) Mr. Orin Hirschman ("Mr. Hirschman"), who is the Managing Member of AIGH Capital Management, LLC and president of AIGH LLC, with respect to shares of Common Stock (as defined in Item 2(d) below) indirectly held through AIGH CM, directly by AIGH LLC and Mr. Hirschman and his family directly. AIGH Capital Management LLC., AIGH Investment Partners LLC, and Mr. Hirschman are hereinafter sometimes collectively referred to as the "Reporting Persons." Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
    (b)Address or principal business office or, if none, residence:

    The principal office and business address of AIGH Capital Management LLC, AIGH Investment Partners LLC, and Mr.Hirschman is: 6006 Berkeley Avenue, Baltimore MD 21209
    (c)Citizenship:

    See Item 2(a) above and Item 4 of each cover page.
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    872381108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1,416,323
    (b)Percent of class:

    3.6  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    1,416,323

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    1,416,323

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Orin Hirschman
     
    Signature:Orin Hirschman
    Name/Title:Orin Hirschman
    Date:05/08/2025
     
    AIGH Capital Management LLC
     
    Signature:Orin Hirschman
    Name/Title:Orin Hirschman, Managing Member
    Date:05/08/2025
    Get the next $TELA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TELA

    DatePrice TargetRatingAnalyst
    3/21/2025$5.00 → $2.00Overweight → Neutral
    Piper Sandler
    5/31/2022$17.00Buy
    Lake Street
    More analyst ratings

    $TELA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President Blizard Jeffrey was granted 104,800 shares, increasing direct ownership by 732% to 119,125 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      6/2/25 4:59:08 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Director Evans Douglas G was granted 7,950 shares, increasing direct ownership by 76% to 18,470 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      5/30/25 4:18:35 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Director O'Brien Federica F. was granted 7,950 shares, increasing direct ownership by 76% to 18,470 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      5/30/25 4:18:27 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grant of an option to purchase 75,000 shares of its common stock and restricted stock units covering 30,000 shares of its common stock to Jim Hagen, the Company's Senior Vice President – Strategic Commercial Operations, with a grant date of June 2, 2025 (the "Grant Date"). T

      6/6/25 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair

      MALVERN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the European launch of OviTex Inguinal Reinforced Tissue Matrix, the only reinforced tissue matrix specifically engineered for laparoscopic and robotic-assisted inguinal hernia repair. This milestone follows the successful U.S. launch of OviTex Inguinal in 2024, where it has achieved over $1 million in sales in its first year and has seen growing adoption by surgeons seeking a tailored, more natural alternative to synthetic mesh for inguinal hernia procedures. OviTex Inguinal is av

      6/3/25 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio Appoints Jeffrey Blizard as President

      MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Jeffrey Blizard as President of TELA Bio, effective immediately. Mr. Blizard, who has served on TELA Bio's Board of Directors for the past year, brings deep industry experience and proven leadership to this expanded role. "This is an important inflection point for TELA Bio," said Antony Koblish, Co-Founder and Chief Executive Officer of TELA Bio. "As we move into the next phase of our growth trajectory, we believe the addition of Jeff—a highly respected l

      6/2/25 8:30:00 AM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    SEC Filings

    See more
    • TELA Bio Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - TELA Bio, Inc. (0001561921) (Filer)

      6/2/25 8:30:24 AM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - TELA Bio, Inc. (0001561921) (Filer)

      5/30/25 4:06:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by TELA Bio Inc.

      SCHEDULE 13G/A - TELA Bio, Inc. (0001561921) (Subject)

      5/30/25 4:03:12 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care